BBS-Bioactive Bone Substitutes Oyj: The subscription period for the second warrant series starts on 22 May 2023 – the subscription price is EUR 0.65 per share

19 May 2023 - 11:00

BBS-Bioactive Bone Substitutes Oyj, Company release, 19 May 2023 at 12.00 p.m. EEST

BBS-Bioactive Bone Substitutes Oyj: The subscription period for the second warrant series starts on 22 May 2023 – the subscription price is EUR 0.65 per share

BBS-Bioactive Bone Substitutes Oyj (BBS) organized a rights issue from May 18 to June 3, 2022. In connection with the share issue, a total of 670,962 warrants from two different series (TO1 and TO2) were also granted to the subscribers. Each warrant gives its owner the right to subscribe for one new share at a discounted price.

Information about the second series of warrants (TO2):

  • Subscription period: For the second warrant series (TO2), the subscription period starts on Monday 22 May 2023 and ends on Friday 2 June 2023.
  • Place of subscription: The subscription place in Finland is the account and asset managers and Hagberg & Aneborn Fondkomission AB in Sweden. The subscription order must be given in accordance with the instructions given by the holder’s account administrator or asset manager.
  • ISIN code: The ISIN code of the warrants (TO2) is FI4000522909.
  • Subscription price: The subscription price is EUR 0.65 or SEK 7.38 per share. The share subscription price (TO2) has been determined by the volume weighted average price of the company’s share on First North Finland between 8 May 2023 and 18 May 2023, with an applied discount of 25 per cent.
  • Trading: Warrants may be traded in Finland on Nasdaq First North Finland until 30 May 2023.

Terms and Conditions of Warrants TO2 are available on the Share issue 2022 website:

For more information:

Ilkka Kangasniemi, CEO,
tel. +358 40 708 0307, e-mail: [email protected]

Certified Advisor:
Nordic Certified Adviser AB, tel. +46 70 551 67 29, [email protected]

BBS in brief

BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lumber problems. Our goal is to provide a new generation of medical products for the treatment of bone damage in orthopaedic surgery. In the pharmaceutical sector, development and research requires perseverance and courage to develop new things. We have evidence of this for over 20 years. Our activities are characterised by top expertise, innovation and employees who are enthusiastic and committed to their work. The ARTEBONE ® in the final stages of product development, and we are looking for a CE marking that enables commercialisation in the EU. We are a company in Oulu with a pharmaceutical factory permit in Reisjärvi.

BBS-Bioactive Bone Substitutes Oyj:n shares are listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

More information:

Provided by: GlobeNewswire
Nasdaq First North GM Helsinki (Finland)
BBS-Bioactive Bone Substitutes Oyj
Bioactive Bone Substitutes is a health technology company, that develops, designs and manufactures innovative bioactive bone-graft substitute implants. Its ortho biological product ARTEBONE, which is based on tricalcium phosphate (TCP) and natural spectrum of bone proteins has the capability of bone regeneration....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More